These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 5575296)

  • 1. Effects of selected hypolipidemic drugs on cell ultrastructure.
    Svoboda DJ; Azarnoff DL
    Fed Proc; 1971; 30(3):841-7. PubMed ID: 5575296
    [No Abstract]   [Full Text] [Related]  

  • 2. Proliferation of microbodies and synthesis of catalase in rat liver. Induction in tumor-bearing host by CPIB.
    Reddy J; Svoboda D
    Am J Pathol; 1971 Apr; 63(1):99-108. PubMed ID: 4323477
    [No Abstract]   [Full Text] [Related]  

  • 3. Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect.
    Azarnoff DL; Svoboda DJ
    Arch Int Pharmacodyn Ther; 1969 Oct; 181(2):386-93. PubMed ID: 4397540
    [No Abstract]   [Full Text] [Related]  

  • 4. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate.
    Moody DE; Reddy JK
    Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):501-10. PubMed ID: 4445568
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
    Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
    Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
    Reddy J; Svoboda D; Azarnoff D
    Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
    [No Abstract]   [Full Text] [Related]  

  • 7. [Peroxisomes and hypolipidemic agents ].
    Heller F; Pourbaix S
    Sem Hop; 1982 Jul; 58(28-29):1712-7. PubMed ID: 6289453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer hypolipidemic agents.
    Kritchevsky D
    Fed Proc; 1971; 30(3):835-40. PubMed ID: 4996475
    [No Abstract]   [Full Text] [Related]  

  • 9. Some morphological effects of 20,25-diazacholesterol (SC-12937) on adrenocortical cells of the Syrian hamster.
    Yates RD; Chen IL; Mascorro JA
    Tex Rep Biol Med; 1968; 26(2):241-8. PubMed ID: 5675210
    [No Abstract]   [Full Text] [Related]  

  • 10. Polydispersity of rat liver peroxisomes induced by the hypolipidemic and carcinogenic agent clofibrate.
    Flatmark T; Christiansen EN; Kryvi H
    Eur J Cell Biol; 1981 Apr; 24(1):62-9. PubMed ID: 7238535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of hypolipidemic drugs. Introduction.
    Azarnoff DL
    Fed Proc; 1971; 30(3):827-8. PubMed ID: 5575294
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of clofibrate on acetyl-CoA carboxylase activity in hepatocytes.
    Harkins JB; Yates RD
    Z Zellforsch Mikrosk Anat; 1971; 119(3):321-5. PubMed ID: 5569050
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-induced and naturally occurring myeloid bodies.
    Hruban Z; Slesers A; Hopkins E
    Lab Invest; 1972 Jul; 27(1):62-70. PubMed ID: 4402449
    [No Abstract]   [Full Text] [Related]  

  • 14. Microbodies in experimentally altered cells. II. The relationship of microbody proliferation to endocrine glands.
    Svoboda D; Azarnoff D; Reddy J
    J Cell Biol; 1969 Mar; 40(3):734-46. PubMed ID: 5765763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rat hepatocyte peroxisomes: ultrastructural alterations following cessation of chronic dietary clofibrate administration.
    Hartman HA; Tousimis AJ
    Experientia; 1969 Dec; 25(12):1248-9. PubMed ID: 5365841
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of some hypocholesterolemic agents on hepatic ulrastructure and microbody enzymes.
    Hruban Z; Mochizuki Y; Goto M; Slesers A; Chou SH
    Lab Invest; 1974 Apr; 30(4):474-85. PubMed ID: 4150963
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of hepatic cholesterol biosynthesis by clofibrate administration.
    White LW
    J Pharmacol Exp Ther; 1971 Aug; 178(2):361-70. PubMed ID: 5570460
    [No Abstract]   [Full Text] [Related]  

  • 18. [Enzyme-inducing activities of hypolipidemic agents and ultrastructural changes of the liver elicited by clofibrate (author's transl)].
    Araki Y; Amagase H
    Fukuoka Igaku Zasshi; 1974 Jul; 65(7):465-72. PubMed ID: 4474120
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of hypolipidemic drugs in the prevention of an orotic acid fatty liver.
    Elwood JC; Richert DA; Westerfeld WW
    Biochem Pharmacol; 1972 Apr; 21(8):1127-34. PubMed ID: 5034198
    [No Abstract]   [Full Text] [Related]  

  • 20. Stimulation of liver catalase synthesis in rats by ethyl-alpha-p-chlorophenoxyisobutyrate.
    Reddy J; Chiga M; Svoboda D
    Biochem Biophys Res Commun; 1971 Apr; 43(2):318-24. PubMed ID: 4996023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.